CoChat

Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design: Lamotrigine in bipolar depression, long-term outcome

van der Loos, Marc LM, Mulder, Paul, Hartong, Erwin GThM, Blom, Marc BJ, Vergouwen, Anton C, van Noorden, Martijn S, Timmermans, Manuela A, Vieta, Eduard, Nolen, Willem A, for the LamLit Study Group* · 2011 · Bipolar Disorders
Cited by 61

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

van der Loos MLM, Mulder P, Hartong EGThM, Blom MBJ, Vergouwen AC, van Noorden MS, Timmermans MA, Vieta E, Nolen WA, for the LamLit Study Group. Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design.Bipolar Disord 2011: 13: 111–117. © 2011 The Authors. Journal compilation © 2011 John Wiley & Sons A/S. Objective: In two previous manuscripts, we described the efficacy of lamotrigine versus placebo as add-on to lithium (followed by the addition of paroxetine in nonresponders) in the short-term treatment of bipolar depression. In this paper we describe the long-term (68 weeks) outcome of that study. Methods: A total of 124 bipolar depressed patients receiving lithium were randomized to addition of lamotrigine or placebo. After eight weeks, paroxetine was added to nonresponders for another eight weeks. Responders continued medication and were followed for up to 68 weeks or until a relapse or recurrence of a depressive or manic episode. Results: After eight weeks, the addition of lamotrigine to lithium was significantly more efficacious than addition of placebo, while after addition of paroxetine in nonresponders both groups further improved with no significant difference between groups at week 16. During follow-up the efficacy of lamotrigine was maintained: time to relapse or recurrence was longer for the lamotrigine group [median time 10.0 months (confidence interval: 1.1–18.8)] versus the placebo group [3.5 months (confidence interval: 0.7–7.0)]. Conclusion: In patients with bipolar depression, despite continued use of lithium, addition of lamotrigine revealed a continued benefit compared to placebo throughout the entire study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1399-5618.2011.00887.x

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 61

Metadata

Authors
van der Loos, M. L., Mulder, P., Hartong, E. G., Blom, M. B., Vergouwen, A. C., van Noorden, M. S., Timmermans, M. A., Vieta, E., Nolen, W. A., & for the LamLit Study Group*
Venue
Bipolar Disorders
Publisher
Wiley
Published
2011-02
Volume
13
Issue
1
Pages
111-117
ISSN
1398-5647 (ISSN-L)
OpenAlex
W2143270976
Cited by
61
References
13
FWCI
5.52
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design: Lamotrigine in bipolar depression, long-term outcome. https://app.cochat.ai/papers/10.1111/j.1399-5618.2011.00887.x
The paper
van der Loos, M. L., Mulder, P., Hartong, E. G., Blom, M. B., Vergouwen, A. C., van Noorden, M. S., Timmermans, M. A., Vieta, E., Nolen, W. A., & for the LamLit Study Group*. (2011). Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design: Lamotrigine in bipolar depression, long-term outcome. Bipolar Disorders. https://doi.org/10.1111/j.1399-5618.2011.00887.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.